Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary unaudited revenues of approximately $105 million for the quarter ended September 30, 2015, an increase of $36 million, or 52%, year over year. Dexcom’s third quarter 2015 revenues are preliminary and subject to adjustment as the Company evaluates the impact of any revenue deferral related to the upgrade programs announced in connection with the Company’s G5 Mobile launch.
“Our third quarter revenues again exceeded our expectations and we couldn’t be more pleased with the performance of our organization,” said Kevin Sayer, Dexcom’s President and Chief Executive Officer. “Demand for our G5 Mobile system has been overwhelming and our pipeline of new patient opportunities is larger than it has ever been. We have worked diligently to fulfill demand by new patients, we have commenced shipping upgrades to existing patients and we expect to complete the upgrade cycle before the end of 2015. There has been some noise in the marketplace recently suggesting that certain payers are seeking to delay payment for CGM, and while we have always stated that payers can be challenging from time to time, we could not deliver a record quarter in terms revenues without meaningful contribution from all major payers.”
How does Dexcom compare to the labstyle dri$ device, which is awaiting FDA approval? Anyone know similarities/differences. Dri$ currently at .36 awaiting approval. Zacks gives it $12 price target with FDA approval.
Latest Afrezza Table.
Far right, yellow column: Stalls at 19%.
First stall since sales started in Feb., 2015.
Peak refill growth rate was in April.
A responder indicated that I should account for last week only having 4 days. I'm pretty sure he is talking about the stock market.
As a diabetic, do you think your diabetes medication is contingent on the stock market being open? Just checking.
MER
Your 52-week High price alert for DXCM was triggered. DXCM reached a price of $71.25 at 02:11:00 PM ET on 05/27/2015 with 421,746 shares traded up to that time.
Definitely fixed price.
In fact, because of the problems the company is throwing in extras at no cost.
The last time I paid to have something done that I would normally do myself was about 25 years ago.
I would do brake maintenance on vehicles myself. But my wife was often complaining that I didn't giver her enough time. So I decided to prove a point and take the vehicle into a brake shop that was popular and had a lot of customers. The job that would cost me about $90 to do within a couple hours effort ended up costing me $450. My wife didn't seem to be disturbed by that. Last time I ever did that. When my eldest son was old enough to drive and I bought him a car, I preached to him the benefits of doing his own maintenance.
Hope you had a fixed price ?
My bad,
I should have made my post clearer.
The one you call flipper. That person's My Stocks at their iHub profile page. Check that out.
For instance, you list EYES, IWM, TNA, TZA at your profile page.
--
As for my stocks, I only have ZNGA, SWKS, and CRUS now, and am holding a lot of cash. Most of the reason for that is because I hired a contractor to do some work on my house, and they've taken up a lot of my time over the last three weeks because they've been screwing up left and right. To do the work, I had to move virtually everything out of my house during the prior week before they arrived. Even my computers were deactivated for a while. Because of all of those issues, I've done virtually nil in terms of trades for four weeks.
And get this -- the estimated time by the contractor to do the work here was 3 days. They took 20 days and the first teem sent out here to do the work got fired by the contractor. I protested the firing and suggested that the company should have more simply sent the workers to a class to teach them how to manage their time better, and also the proper way to interact with customers.
Regarding the work on the house, there's virtually nothing I can't do myself and already have the tools for, but I decided to take a vacation from that and hire somebody else. Big mistake. The job was finally finished today about 3 hours ago, and now I have the fun of moving everything back into the house -- but only after I clean up the mess. Concrete dust is everywhere, and it didn't matter if doors and cupboards were closed. The cleaning alone could take two full days, then another week to move everything back into the house.
Ugh ... I'm so tired.
JLS
Sorry. No longer have list of your stocks.
Re flipper,
Check My Stocks.
The Centers for Diseases Control and Prevention estimates that 29.1 million Americans suffer from diabetes, with that number reaching as high as 387 million around the globe. By 2035, the worldwide number is estimated to grow to as many 592 million patients.
Diabetes is a chronic disease caused by the body's inability to produce or effectively utilize insulin, which prevents the body from adequately regulating blood glucose levels.
Diabetes is typically classified into two major groups: type 1 and type 2.
Type 1 diabetes is an autoimmune disorder characterized by the body attacking its own insulin-producing cells of the pancreas. Without any natural insulin production, patients with type 1 diabetes must rely on frequent insulin injections in order to regulate and maintain blood glucose levels. As of 2012, about 1.25 million American had been diagnosed with Type 1 diabetes.
Type 2 diabetes is a metabolic disorder that results when the body is unable to produce sufficient amounts of insulin or becomes insulin resistant, and this type is much more common than type 1. About 19 million Americans have been diagnosed with type 2 diabetes, and a further 8.1 million have type 2 but remain undiagnosed.
Treating diabetes is both complicated and costly. The most recent estimates from the American Diabetes Association indicate that total costs to treat diabetes in the U.S. reached $245 billion in 2012 alone, up from $174 billion in 2007.
It's no surprise that a market with that level of spending has attracted investors' attention.
There are plenty of ways for investors to gain exposure to the diabetes treatment market, such as Big Pharma companies like Sanofi, Novo Nordisk, and Eli Lilly, who produce a range of drugs used to treat the disease. On the opposite end of the diversity spectrum, MannKind Incorporated (NASDAQ: MNKD ) joined the game recently with its launch of Afrezza, an innovative inhaled insulin that eliminates the need for patients to take shots. Since MannKind has only this one drug approved, it is higher risk than its larger competitors, but it is more of a pure play on the diabetes treatment market.
On the drug delivery side, investors can take a stake in insulin pump manufactures like Medtronic, Insulet, or Tandem Diabetes, all of which have products on the market for insulin delivery to diabetics.
However, there is another company I've had my eye on for a few years, and its been one of my biggest mistakes as an an investor that I've never personally bought shares. The company has been a massive long winner, up a market-crushing 560% since going public in 2005 , leaving investor favorite MannKind in the dust. That company is Dexcom (NASDAQ: DXCM ) .
DXCM Chart
Dexcom produces and sell a product called a continuous glucose monitor, which is a two-part device designed to shows users what their blood glucose level is continuously. Currently, most patients with diabetes check their glucose levels with a meter that requires the user to add a drop of blood to a strip to get a point-in-time reading. The problem with this method is that patients and providers do not get an accurate reading on what is happening with the patient's blood sugars throughout the day, as glucose levels can fluctuate rapidly.
Dexcom's system shows a continuous graph of the patient's blood sugars levels, which can lead to better decisions about insulin dosages, ultimately providing for much better blood sugar control.
Source: Dexcom.
Dexcom offers investors the terrific razor-and-blades business model, as it sells its Dexcom Seven Plus starter kits to patients, who then use the sensor for up to seven days before they throw the sensor away and put another one on.
Source: Dexcom 2014.
Dexcom's solution has enjoyed rapid adoption since launching in 2006, and full-year revenue jumped an impressive 62% in 2014 to $259.2 million. Gross margins for the company have been going up, and in Q4 2014, they hit a very impressive 70%, which allowed the company to generate a profit for the first time ever. The balance sheet is strong as well, with $83 million in cash and equivalents versus $3 million in debt.
Huge opportunity ahead
Dexcom is giving investors plenty of reasons to believe growth will remain strong in the years ahead. The system received expanded approval in February 2014 for the pediatric market, providing a meaningful tailwind for the company.
The company also has announced partnerships with several insulin pump manufacturers that will allow for the displaying of Dexcom's sensor readings directly on the pump itself, which eliminates the need to carry a separate Dexcom receiver.
Source: Animas
Animas Corp.'s Vibe insulin pump has this feature built in and received FDA approval in December 2014. Tandem Diabetes Care's T:Slim pump is slated to have this feature as well, and this version is currently pending FDA approval. Dexcom has also announced a similar agreement with Insulet Corp.'s OmniPod system.
Dexcom is only scratching the surface internationally, as well -- the company only generated 14% of its revenue outside the U.S. in 2014. Lastly, Dexcom has announced that its system will work with the Apple Watch, giving patients a much more convenient way to monitor what is happening with their blood sugar.
Analysts predict the good times are going to continue to roll, with revenue expected to climb another 39% this year to $360 million and reach $489 million in 2016. As the company matures and economies of scale set in, margins should expand nicely, providing a big boost to the bottom line.
All for a price
Dexcom shares can hardly be called cheap, as they are currently trading at about 20 times 2014 sales.
However, given the opportunity presented by such a large market, Wall Street is understandably excited about the company's future, and it's been bidding up shares to match the opportunity, particularly given that the company is finally profitable.
There is a chance the stock price has gotten ahead of itself, but given that Dexcom has proven its technology is well-liked by patients and providers, and has plenty of room for growth ahead, the company remains my favorite way to invest in diabetes.
.
DexCom just nailed FDA approval for its mobile monitoring device.
Source: FDA permits marketing of mobile medical apps for continuous glucose monitoring
took profit here after buying at open. Thought it would go much higher but can't complain.
Now up 1.9%, thought vol would be a bit higher and pps as well, but maybe a slower reaction to news this am.
Innovative Dexcom G4® PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2 to 17 Years
http://ih.advfn.com/p.php?pid=nmona&article=60904541
Dexcom’s Innovative Diabetes Monitoring Device Recognized For Outstanding Achievement at Consumer Electronics Show (CES)
http://ih.advfn.com/p.php?pid=nmona&article=60648346&symbol=DXCM
DexCom, Inc. Reports Third Quarter 2013 Financial Results
http://ih.advfn.com/p.php?pid=nmona&article=59912079
DexCom Inc. Reports First Quarter 2013 Financial
http://ih.advfn.com/p.php?pid=nmona&article=57399906
8:01AM Dexcom reports that the U.S. FDA approves the Dexcom G4 PLATINUM continuous glucose monitor (DXCM) 14.76 : Co announced that the U.S. Food and Drug Administration has approved its eagerly anticipated new continuous glucose monitoring system, the Dexcom G4 PLATINUM. Clinical trials report up to ~19% improvement in overall accuracy for the Dexcom G4 PLATINUM compared to the Seven Plus, and ~a 30% improvement in accuracy in the hypoglycemia range (i.e., when blood glucose is less than 70mg/dl). The overall accuracy and ease of use for the Dexcom G4 PLATINUM sets a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available.
~ Wednesday! $DXCM ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $DXCM ~ Earnings expected on Wednesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=DXCM&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=DXCM&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=DXCM
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=DXCM#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=DXCM+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=DXCM
Finviz: http://finviz.com/quote.ashx?t=DXCM
~ BusyStock: http://busystock.com/i.php?s=DXCM&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=DXCM >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
DexCom Announces the Sale of 4.7 Million Shares of Common Stock
DexCom, Inc. (Nasdaq: DXCM), today announced the sale of 4.7 million shares of its common stock pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner. The last reported sale price of our common stock as reported by the Nasdaq Global Market on May 4, 2011 was $16.42 per share.
The Company expects to use the net proceeds from the sale of the shares for working capital and general corporate purposes. Closing of the offering is expected to occur on or about May 10, 2011, subject to customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 705,000 shares of common stock to cover over-allotments, if any.
The offering is being made pursuant to an effective shelf registration statement. Before you invest, you should read the base prospectus in such shelf registration statement, the prospectus supplement, when available, and other documents we have filed with the Securities and Exchange Commission for more complete information about us and this offering. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to the offices of Canaccord Genuity, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, phone: 617-371-3900. Alternatively, you may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company's products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company's inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ended March 31, 2011, as filed with the Securities and Exchange Commission on May 3, 2011.
DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results
Date : 03/03/2011 @ 4:01PM
Dexcom (NASDAQ:DXCM)
DexCom, Inc. (Nasdaq:DXCM) today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2010.
For the full-year ended December 31, 2010, product revenue grew to $40.2 million, an increase of 123% from the $18.0 million in product revenue reported for 2009, and total revenue grew to $48.6 million, an increase of 64% from 2009. Product revenue totaled $13.6 million for the fourth quarter of 2010, an increase of 105% from the $6.6 million in product revenue reported for the comparable period in 2009. Total fourth quarter 2010 revenue, which included development grant and other revenue, was $15.6 million, an increase of 49% from the comparable period in 2009. Product gross margin totaled $5.9 million and $14.1 million for the three and twelve months ended December 31, 2010, compared to gross margin of $1.2 million and gross deficit of $(0.2) million for the three and twelve months ended December 31, 2009. The Company reported a net loss of $9.8 million, or $0.16 per share, and $55.2 million, or $0.97 per share, for the three and twelve months ended December 31, 2010, compared to $11.5 million, or $0.25 per share, and $53.5 million, or $1.21 per share, for the three and twelve months ended December 31, 2009. The net loss for 2010 included $22.3 million in non-cash expenses, comprised primarily of share-based compensation, loss on debt extinguishment upon conversion of convertible notes, depreciation, and amortization.
Total cost of sales for the twelve months ended December 31, 2010 totaled $30.2 million compared to $26.0 million for 2009. The increase was primarily due to additional product sales offset by lower development expenses relating to our continuing performance obligations under development and collaboration agreements entered into during 2008. Research and development expense totaled $23.2 million in 2010 compared to $14.3 million in 2009. Changes in research and development expense included additional salaries and payroll related costs, share-based compensation, and facility costs. Selling, general and administrative expense totaled $40.5 million in 2010 compared to $35.2 million in 2009, with the change primarily due to additional selling, information technology, and international business development costs, including increased share-based compensation. As of December 31, 2010, the Company had $47.1 million in cash and marketable securities, and $1.7 million in restricted cash.
Conference Call
Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com under the investor webcast section and will be archived for future reference. To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the participant code "28602160" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company’s products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company’s inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company’s development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's annual report on Form 10-K for the period ending December 31, 2010, as filed with the Securities and Exchange Commission on March 3, 2011.
DexCom, Inc.
Consolidated Balance Sheets
(In thousands—except par value data)
As of December 31,
2010 2009
Assets
Current assets:
Cash and cash equivalents $ 4,889 $ 3,577
Short-term marketable securities, available-for-sale 42,224 24,439
Accounts receivable, net 6,671 3,490
Inventory 8,112 2,641
Restricted cash 1,439 —
Prepaid and other current assets 2,690 2,773
Total current assets 66,025 36,920
Property and equipment, net 10,763 6,422
Restricted cash 275 2,414
Other assets 101 1,192
Total assets $ 77,164 $ 46,948
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued liabilities $ 5,350 $ 5,745
Accrued payroll and related expenses 5,730 4,406
Current portion of long-term debt 525 900
Current portion of deferred revenue 3,524 7,745
Total current liabilities 15,129 18,796
Other liabilities 1,042 840
Long-term debt, net of current portion — 45,757
Total liabilities 16,171 65,393
Commitments and contingencies
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value per share, 5,000 shares authorized; no shares issued and outstanding at December 31, 2010 and December 31, 2009, respectively. — —
Common stock, $0.001 par value per share, 100,000 authorized; 62,360 and 62,078 shares issued and outstanding, respectively, at December 31, 2010, and 46,324 and 46,045 shares issued and outstanding, respectively, at December 31, 2009 62 46
Additional paid-in capital 407,375 272,730
Accumulated other comprehensive loss (66 ) (13 )
Accumulated deficit (346,378 ) (291,208 )
Total stockholders’ equity (deficit) 60,993 (18,445 )
Total liabilities and stockholders’ equity (deficit) $ 77,164 $ 46,948
DexCom Inc.
Consolidated Statements of Operations
(In thousands—except per share data)
Three Months Ended
December 31, Twelve Months Ended
December 31,
2010 2009 2010 2009
Product revenue
$
13,592
$ 6,632 $ 40,175 $ 18,036
Development grant and other revenue 2,044 3,839 8,456 11,657
Total revenue 15,636 10,471 48,631 29,693
Product cost of sales 7,664 5,478 26,104 18,216
Development and other cost of sales 983 886 4,084 7,816
Total cost of sales 8,647 6,364 30,188 26,032
Gross margin 6,989 4,107 18,443 3,661
Operating expenses
Research and development 6,902 4,172 23,227 14,294
Selling, general and administrative 9,973 9,397 40,506 35,200
Total operating expenses 16,875 13,569 63,733 49,494
Operating loss (9,886 ) (9,462 ) (45,290 ) (45,833 )
Other income (loss) 63 (17 ) 63 —
Interest income 22 48 95 354
Interest expense (8 ) (2,098 ) (1,548 ) (8,045 )
Loss on debt extinguishment upon conversion of convertible debt (3 ) — (8,490 ) —
Net loss ($9,812 ) ($11,529 ) ($55,170 ) ($53,524 )
Basic and diluted net loss per share ($0.16 ) ($0.25 ) ($0.97 ) ($1.21 )
Shares used to compute basic and diluted net loss per share 60,367 45,980 56,881 44,347
DexCom Schedules Second Quarter Earnings Release and Conference Call for August 3, 2010
Date : 07/27/2010 @ 8:30AM
Source : Business Wire
Stock : DexCom, Inc. (DXCM)
Quote : 11.93 0.13 (1.10%) @ 7:22AM
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2010 financial results after market close on Tuesday, August 3, 2010. Management will hold a conference call to review the company's second quarter 2010 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call
will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com under the investor webcast section and will be archived for future reference.
To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the confirmation number "27580067" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.
DXCM makes new 52 week high today. It's had one heck of a run lately.
WOW, we just blew through $9.00 with no resistance. Looking good here.
Nice run today after yesterdays earnings. very positive CC on the website.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
115
|
Created
|
06/08/09
|
Type
|
Free
|
Moderators |
Company web site.
DexCom, Inc., a medical device company, engages in the design, development, and commercialization of continuous glucose monitoring systems for people with diabetes in the United States. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for continuously monitoring blood glucose levels in patients hospitalized for various conditions. The company was founded in 1999 and is headquartered in San Diego, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |